Why Microsoft's Yammer Buyout Matters in Pharma

More News:

• 05/24/2013 Merck Stops Development of Parkinson’s DrugFrom Bloomberg

  Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesn’t work

• 05/23/2013 French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News

  Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.

• 05/22/2013 Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online

  Novo A/S has acquired Xellia Pharmaceuticals of Norway

• 05/22/2013 Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online

  Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan

• 05/22/2013 New Asthma Drug Offers Hope for PatientsFrom Forbes

  An experimental asthma drug could give new hope to patients for whom existing medicines are not enough

• 05/21/2013 Syrian Pharma Production Nearly Halted by WarFrom AFP

  A shortage of foreign currency has brought production to a near halt in Syria

• 05/21/2013 Camfil APC Opens Manufacturing Plant in the UKFrom Camfil

  Camfil announced the grand opening of its new 40,000-sq.-ft. facility

• 05/21/2013 Actavis Acquiring Warner Chilcott for $8.5BFrom AP

  Actavis to buy Warner Chilcott in an all-stock transaction

• 05/17/2013 Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics

  NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration

• 05/16/2013 Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com

  Agreement creates unique strategic collaboration for development and clinical trial execution

• All news »